| First Author | Hogarty MD | Year | 2012 |
| Journal | Cancer Cell | Volume | 21 |
| Issue | 2 | Pages | 145-7 |
| PubMed ID | 22340587 | Mgi Jnum | J:181466 |
| Mgi Id | MGI:5311490 | Doi | 10.1016/j.ccr.2012.01.018 |
| Citation | Hogarty MD, et al. (2012) PI3King on MYCN to Improve Neuroblastoma Therapeutics. Cancer Cell 21(2):145-7 |
| abstractText | MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN. |
